Evidence map›Paper›PMID 35594950›Full record

ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Susceptibility to first choice antimicrobial treatment for urinary tract infections to Escherichia coli isolates from women urine samples in community South Brazil.

Zuleica Naomi Tano, Renata K Kobayashi, Evelyn Poliana Candido, Juliana Buck Dias, Luis Felipe Perugini, Eliana Carolina Vespero, Wander Rogerio Pavanelli

Open access · goldAbstract read
In one paragraph

Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Fluoroquinolone resistantFrontiers in microbiology · 2026
    Article
  2. Article
  3. Article
  4. Dominance ofMicrobial genomics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zuleica Naomi TanoUniversidade Estadual de Londrina, Departamento de Medicina Interna, Londrina, PR, Brazil. Electronic address: zntanno@uel.br.
Renata K KobayashiUniversidade Estadual de Londrina, Departamento de Microbiologia, Londrina, PR, Brazil.
Evelyn Poliana CandidoUniversidade Estadual de Londrina, Departamento de Patologia, Análises Clínicas e Toxicológicas, Londrina, PR, Brazil.
Juliana Buck DiasUniversidade Estadual de Londrina, Departamento de Patologia, Análises Clínicas e Toxicológicas, Londrina, PR, Brazil.
Luis Felipe PeruginiUniversidade Estadual de Londrina, Departamento de Patologia, Análises Clínicas e Toxicológicas, Londrina, PR, Brazil.
Eliana Carolina VesperoUniversidade Estadual de Londrina, Departamento de Patologia, Análises Clínicas e Toxicológicas, Londrina, PR, Brazil.
Wander Rogerio PavanelliUniversidade Estadual de Londrina, Centro de Ciências Biológicas, Departamento de Ciências Biológicas, Laboratório de Imunoparasitologia de Doenças Negligenciadas e Câncer (LIDNC), Londrina, PR, Brazil.
Universidade Estadual de Londrina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

E. coli is the main pathogen of UTI. It is important to be aware the local epidemiological data for an appropriate initial treatment. Resistance to antimicrobial agents has increased, especially to first-choice antibiotics in the treatment of cystitis. There are few studies on the sensivity profile of community uropathogen in our region.

objectiveTo characterize antimicrobials the sensitivity profile to E. coli isolated from urocultures of women treated at Basic Health Units and Emergency Care Units of Londrina- Paraná- Brazil during a period of 12 months (June 1, 2016 to June 1, 2017). METHODOLOGY: A cross-sectional study was carried out from June 2016 to June 2017. All urine samples collected in the Basic Health Units and Emergency Departments in the city of Londrina (Paraná State, Brazil) were sent to a Central Laboratory where the identification and antimicrobial susceptibility testing were performed. Clinical Laboratory Standards Institute (CLSI) breakpoints were used for the interpretation of susceptibility testing results.

results56,555 urine cultures were performed in the period, of which 8,832 were positive, of which 5,377 were women. Of these samples, 4.7% were enterobacteria producing extended-spectrum beta-lactamases (ESBL) and 15.5% resistant to quinolones. TMP- SMX was resistant in more than 30% of the samples in all age groups. Among quinolone-resistant isolates, resistance to cephalothin, ampicillin and sulfamethoxazole-trimethoprim was greater than 60%. Nitrofurantoin was the only antimicrobial that showed 90% of sensitivity.

conclusionThe antimicrobials sensitivity profile was similar to that reported in the literature, with TMP- SMX resistance greater than 30% in the studied samples. Nitrofurantoin maintains high sensitivity rates greater than 90%. Resistance to quinolones increases proportionally with age, as well ESBL.

Indexed as

Anti-Infective AgentsEscherichia coli InfectionsQuinolonesUrinary Tract InfectionsAnti-Bacterial Agentsbeta-LactamasesBrazilCross-Sectional StudiesDrug Resistance, BacterialEscherichia coliFemaleHumansMicrobial Sensitivity TestsNitrofurantoinTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsAnti-Infective Agentsbeta-LactamasesNitrofurantoinQuinolonesTrimethoprim, Sulfamethoxazole Drug CombinationBacteriuriaDrug resistanceEscherichia coliUrinary tract infectionUropathogenic

Identifiers

PMID35594950
PMCPMC9217753
OpenAlexW4280543062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.